Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

NCT00687297 is registered in ClinicalTrials.gov with PrECOG, LLC. as lead sponsor.

NCT NCT00687297
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00687297 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
PrECOG, LLC.
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2008
Completion date
April 30, 2011
Enrollment
162 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, non small cell lung cancer